USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS

Sivkovich S.A., Orel V.E, Dzyatkovskaya N.N.

Objective of a study — analysis of clinical use of machanochemically activated (MA) charged nanoparticles of doxorubicin (DR) as a factor lim­ iting complications in polychemotherapy (PCT) of patients with malignant lymphomas. A study was performed in 17 patients with non­Hodgkin’s lym­ phomas (NHL), 23 patients with Hodgkin’s lym­ phomas (HL) and 60 non­inbred rats with Pliss’ lymphosarcoma. Mechanochemical activation of charged nanoparticles DR was performed with in­ tensity of power supply of 20 W/g. Anti­tumor ef­ fect of MA DR on the animals with Pliss’ lympho­ sarcoma was 1,5­fold more effective than the effect of officinal DR. During PCT of HL and NHL pa­ tients using of MA DR decreased complications dur­ ing and some days after sessions of chemotherapy by 41% as well as increased frequency of complete remission by 35%. Use of MA DR in schedules of PCT increased 5­year survival of NHL patients by 9% and HL patients by 24%. Use of MA nanopar­ ticles DR in the schedules of PCT of HL and NHL patients limits complications and increases 5­year survival of patients.